{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"A complete response is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.","groups":[{"description":"* Daratumumab will be administered in three phases: Induction, consolidation and maintenance\n* During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day\n* During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle\n* During maintenance, daratumumab will be administered on day 1 of each 28-day cycle\n\nDaratumumab: Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories","id":"OG000","title":"Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only those participants who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Complete Response","type":"SECONDARY","unitOfMeasure":"Participants"}